Skip to main content
SpringerLink
Log in

Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations

  • Research Letter
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Mitra S, Florez ID, Tamayo ME, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA. 2018;319(12):1221–38. https://doi.org/10.1001/jama.2018.1896.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Parkerson S, Philip R, Talati A, Sathanandam S. Management of patent ductus arteriosus in premature infants in 2020. Front Pediatr. 2021;8: 590578. https://doi.org/10.3389/fped.2020.590578.

    Article  PubMed  PubMed Central  Google Scholar 

  3. GlaxoSmithKline Consumer Healthcare ULC. Ibuprofen. July 20, 2006. Updated March 12, 2021. https://pdf.hres.ca/dpd_pm/00060541.PDF [Accessed 15 May 2023].

  4. Grauso M, Lan A, Andriamihaja M, Bouillaud F, Blachier F. Hyperosmolar environment and intestinal epithelial cells: impact on mitochondrial oxygen consumption, proliferation, and barrier function in vitro. Sci Rep. 2019;9(1): 11360. https://doi.org/10.1038/s41598-019-47851-9.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lueschow SR, Kern SL, Gong H, et al. Feeding formula eliminates the necessity of bacterial dysbiosis and induces inflammation and injury in the Paneth cell disruption murine NEC model in an osmolality-dependent manner. Nutrients. 2020;12(4):900. https://doi.org/10.3390/nu12040900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Commentary on breast-feeding and infant formulas, including proposed standards for formulas. Pediatrics. 1976;57(2):278–85.

  7. Shah DD, Kuzmov A, Clausen D, et al. Osmolality of commonly used oral medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther. 2021;26(2):172–8. https://doi.org/10.5863/1551-6776-26.2.172.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Coombs RC, Morgan ME, Durbin GM, Booth IW, McNeish AS. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child. 1990;65(10 Spec No):1067–71. https://doi.org/10.1136/adc.65.10_spec_no.1067.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shulhan J, Dicken B, Hartling L, Larsen BM. Current knowledge of necrotizing enterocolitis in preterm infants and the impact of different types of enteral nutrition products. Adv Nutr. 2017;8(1):80–91. https://doi.org/10.3945/an.116.013193.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Johnson & Johnson Consumer Inc. Motrin: infants’ drops; 2016. https://docs.google.com/document/d/1k2VG2_FDXsyuHK--BGroA-nhtb8En6hmXwf2NphvUkg/edit [Accessed 30 Nov 2023].

  11. Gillam-Krakauer M, Hagadorn JI, Reese J. Pharmacological closure of the patent ductus arteriosus: when treatment still makes sense. J Perinatol. 2019;39(11):1439–41. https://doi.org/10.1038/s41372-019-0518-3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to Lauren Ferruccio, PharmD, the clinical pharmacist at McMaster Children’s Hospital, NICU, who contributed ideas related to the conceptualization of the study.

Author information

Authors and Affiliations

  1. Neonatal Intensive Care Unit, McMaster Children’s Hospital, Hamilton, ON, Canada

    Jaemaela del Rosario & Ali McBryde

  2. Department of Pediatrics, Division of Neonatology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4 L8, Canada

    Gerhard Fusch & Samira Samiee-Zafarghandy

  3. Faculty of Health Sciences, School of Nursing, McMaster University, Hamilton, ON, Canada

    Katelyn Sushko

  4. Department of Pediatric Pharmacology and Pharmacometrics, University Children’s Hospital Basel, Basel, Switzerland

    John van den Anker

  5. Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA

    John van den Anker

Authors
  1. Jaemaela del Rosario
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhard Fusch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali McBryde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katelyn Sushko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John van den Anker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samira Samiee-Zafarghandy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samira Samiee-Zafarghandy.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflict of Interest

Jaemaela del Rosario, Gerhard Fusch, Ali McBryde, Katelyn Sushko, John van den Anker, and Samira Samiee-Zafarghandy have no conflicts of interest that are directly relevant to the content of this article.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

All relevant data for this study are included in the article. Data sets generated and/or analyzed during this study are available from the corresponding author upon reasonable request.

Code Availability

Not applicable.

Author Contributions

SS-Z and JdR conceptualized the study. SS-Z designed the study. GF collected and analyzed the data. AM and KS contributed to the study design. JdR conducted the literature search and drafted the initial manuscript. SS-Z and JvdA provided valuable input that enhanced the manuscript quality. All authors have seen and approved the final version of the manuscript for submission.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

del Rosario, J., Fusch, G., McBryde, A. et al. Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations. Pediatr Drugs 26, 205–207 (2024). https://doi.org/10.1007/s40272-023-00617-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-023-00617-3

Search

Navigation